Medium-chain triglyceride supplementation under a low-carbohydrate formula is a promising therapy for adult-onset type II citrullinemia.
Mol Genet Metab Rep
; 1: 42-50, 2014.
Article
en En
| MEDLINE
| ID: mdl-27896073
ALP, serum alkali phosphatase; ALT, alanine aminotransferase; ASS1, argininosuccinate synthetase 1; AST, aspartate aminotransferase; Adult-onset type II citrullinemia (CTLN2); BMI, body mass index; CTLN2, adult-onset type II citrullinemia; ChE, cholinesterase; Citrin deficiency; LDH, lactate dehydrogenase; MCFA, medium-chain free fatty acids; MCT, medium-chain triglycerides; Malate-aspartate shuttle; Medium-chain triglycerides (MCT); NICCD, neonatal intrahepatic cholestasis; Neonatal intrahepatic cholestasis (NICCD); PPAR, peroxisome proliferator-activated receptor; PSTI, pancreatic secretory trypsin inhibitor; SLC25A13; TIBC, total iron-binding capacity; UIBC, unsaturated iron-binding capacity; γ-GTP, gamma-glutamyl transpeptidase
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2014
Tipo del documento:
Article